The Food and Drug Administration is convening a panel of outside experts for a two-day meeting starting Thursday to make recommendations on whether compounding pharmacies should be allowed to make some of the most popular injectable peptides
Animal Research Context: Scaling from Rodents Preclinical studies with Dihexa and angiotensin IV analogues employed doses that ranged considerably depending on species, route, and outcome measured: Intravenous (IV) Administration Animal studies using intravenous dosing (which bypasses absorption barriers and achieves near-complete bioavailability) reported cognitive and neuroprotective effects at: 0.1 to 2.0 mg/kg in rodent studies (McCoy et al., 2013) Doses at the higher end of this range (12 mg/kg IV) produced robust behavioral effects For a 70 kg human, equivalent to 70140 mg total IV dose (crude extrapolation) However, direct extrapolation from rodents to humans is unreliable due to differences in metabolism, brain penetration, and receptor sensitivity Intraperitoneal (IP) Administration IP dosing (injection into the abdominal cavity, with slower absorption than IV) showed effects at: Up to 10 mg/kg in some studies Lower bioavailability than IV, requiring higher nominal doses for similar effects This route is not practical for human use Why Rodent Dosing Doesn't Directly Translate Rodent pharmacokinetics differ substantially from humans
BMRB codes of previously published resonance assignments used in this study are 50398 (human FOXO4 FH domain), 50402 (human FOXO4 CR3), 51125 (human p53 TAD2), 51124 (human p53 194), and 51753 (human p53 DBD)
Patients with documented B12 sensitivity or MTHFR methylation variants can ask their provider about the Semaglutide/Glycine variant, which uses glycine and B6 as the carrier instead
Often, treatment is started with a diuretic drug or a so-called ACE-inhibitor
Xiao W, Jiang W, Chen Z, Huang Y, Mao J, Zheng W
